Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal Vascular Biology & Cancer Microenvironment Laboratory, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal Translational Oncobiology Laboratory, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal.
Dermatol Online J. 2023 Apr 15;29(2). doi: 10.5070/D329260768.
Dermatomyositis (DM) is a systemic autoimmune disorder characterized by proximal myopathy and dermatological findings. Approximately 15-30% of DM cases emerge as a paraneoplastic syndrome caused by a concomitant malignancy. Although more rare, in cancer patients DM has also been reported as a possible result of toxicity of some antineoplastic agents, such as taxanes and monoclonal antibodies. Herein, we report a 35-year-old woman with metastatic breast cancer who presented with skin lesions after initiation of paclitaxel and anti-HER2 agents. Clinical, laboratory, and histological findings were consistent with the diagnosis of DM.
皮肌炎（DM）是一种以近端肌病和皮肤表现为特征的系统性自身免疫性疾病。约 15-30%的 DM 病例表现为伴随恶性肿瘤的副肿瘤综合征。尽管较为罕见，但在癌症患者中，DM 也有报道是某些抗肿瘤药物（如紫杉醇和单克隆抗体）毒性的可能结果。在此，我们报告了一例 35 岁的转移性乳腺癌女性患者，在开始使用紫杉醇和抗 HER2 药物后出现皮肤病变。临床、实验室和组织学检查结果符合 DM 的诊断。
